Original articlePostinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept
Section snippets
Methods
This multicenter, retrospective cohort study received approval from the institutional review board (IRB) at Wills Eye Hospital and central Western IRB. The participating centers in this study include: The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania, USA; Associated Retinal Consultants at William Beaumont Hospital, Royal Oak, Michigan, USA; Retina Consultants of Houston, Houston, Texas, USA; Ophthalmic Consultants of Boston, Boston, Massachusetts, USA;
Results
A total of 183 cases of endophthalmitis were identified from 503 890 anti-VEGF injections (1/2753 injections, 0.036%). Baseline characteristics for the 3 anti-VEGF agents are summarized in Table 1. From a total of 153 812 bevacizumab injections, 60 cases (1/2563 injections, 0.039%) of endophthalmitis occurred. For patients receiving ranibizumab injections, a total of 109 cases of postinjection endophthalmitis were reported from 309 722 ranibizumab injections (1/2841 injections, 0.035%). In the
Discussion
This study demonstrated that the rate of postinjection endophthalmitis is similar among eyes receiving intravitreal injections of bevacizumab, ranibizumab, and aflibercept. In addition, the percentage of culture-positive endophthalmitis cases was similar among the 3 agents. Coagulase-negative Staphylococcus and Streptococcus species were the first and second most commonly isolated organisms, respectively, for patients receiving bevacizumab and ranibizumab. For the aflibercept group,
References (24)
- et al.
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study
Ophthalmology
(2009) - et al.
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase iii trials
Ophthalmology
(2013) - et al.
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study
Ophthalmology
(2011) - et al.
Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study
Ophthalmology
(2011) - et al.
Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents
Ophthalmology
(2011) - et al.
An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab
Am J Ophthalmol
(2012) - et al.
Noninfectious inflammation after intravitreal injection of aflibercept: clinical characteristics and visual outcomes
Am J Ophthalmol
(2014) - et al.
Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections
Ophthalmology
(2012) - et al.
Conjunctival flora antibiotic resistance patterns after serial intravitreal injections without postinjection topical antibiotics
Am J Ophthalmol
(2014) - et al.
The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection
Ophthalmology
(2014)
Cited by (91)
Differential diagnosis of endophthalmitis after intravitreal drug injection for age related macular degeneration: Sterile vs. infectious
2023, Archivos de la Sociedad Espanola de OftalmologiaGuidance on brolucizumab management recommendations
2022, Archivos de la Sociedad Espanola de OftalmologiaThe ideal intravitreal injection setting: office, ambulatory surgery room or operating theatre? A narrative review and international survey
2023, Graefe's Archive for Clinical and Experimental OphthalmologyThe occurrence of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor drugs
2023, Recent Advances in Ophthalmology
Supplemental Material available at AJO.com.